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Mutations in the genes encoding β-hexosaminidase α (HEXA) and β (HEXB) subunits, and GM2-activator protein (GM2A), cause Tay-Sachs disease (TSD), Sandhoff-Jatzkewitz disease, and GM2 activator deficiency, but clinically these conditions are indistinguishable. [2] [3] [4] [5] Hex A isozyme requires dimerization of α and β subunits for enzymatic activity, whereas Hex S and Hex B are homodimers of α and β subunits, respectively. [6] [7] [8] Of the stored glycoconjugates only ganglioside GM2 has an absolute requirement for Hex A and cofactor GM2-activator protein for its breakdown. 9 Failure to cleave β-N-acetyl-hexosamine residues from the nonreducing ends of glycoconjugates leads to lysosomal storage in neural tissue and relentless neurodegeneration. In common with many other neurological insults, there is activation of microglia/macrophages and astrocytes with concomitant production of inflammatory mediators. 10 The inflammatory response may precede the clinical manifestations, 11 and further perpetuate neurological injury. 12 GM2 gangliosidoses occur naturally in several species, 13, 14 but the mouse is more amenable for testing new therapies. Two Sandhoff mouse models have been generated by targeted disruption of the Hexb gene. 15 , 16 Sandhoff mice appear normal for about the first three months of life, but thereafter they rapidly deteriorate and die between the age of 4 and 5 months. Glycoconjugate accumulation extends to most regions of the brain and spinal cord. Motor dysfunction, which includes spasticity, muscle weakness, rigidity, tremor and ataxia is stereotypic and reflects disease in the cerebrum and cerebellum. The manifestations of disease in Sandhoff mice closely mirror those observed in the acute form of GM2 gangliosidosis in human infants.
GM2 gangliosidosis mouse models have been extensively used in the search for an effective treatment of these devastating diseases. Approaches taken include substrate reduction therapy, 17 bone marrow, 18 and neural stem cell transplantation, 19, 20 anti-inflammatory drugs, 21 intraventricular delivery of purified protein, 22 and adenoviral 23 and lentiviral vectors 24 driving expression of the corrective enzyme. Unfortunately, survival and functional outcomes of these therapies have been modest. Pharmacological chaperons 25 are being tested in clinical trials, but these are predicted to benefit late-onset forms where residual enzyme is present.
We have previously shown that intracranial delivery of recombinant adeno-associated viral vectors (rAAV) expressing the β-subunit of β-hexosaminidase (rAAVβ) alone delays disease onset in the Sandhoff mouse. It has been predicted however, that in both TSD and SD, overexpression of one of the transgenes would rapidly deplete the pool of its endogenous subunit partner. Since successful clinical application of gene therapy will require robust synthesis of Hex A, simultaneous coexpression of α and β subunits is necessary. 23, 26 Coinjection of low-titer rAAV-expressing human β-hexosaminidase α (rAAVα) and β subunits (rAAVα + rAAVβ), allowed survival of 20% of the animals to at least 1 year of age. 27 To inform the design of therapeutic trials in human patients, we set out to define: (i) the minimum number of injections necessary to achieve global delivery of enzyme to the brain and spinal cord for complete resolution of disease; (ii) those sites in the brain with connections that would promote axonal transport of the viral vectors and distribution of β-hexosaminidase; and (iii) whether it is possible to use therapeutic gene transfer to discriminate between the different contributions of disease in the cerebral cortex and cerebellum to spasticity or tremor and ataxia, respectively. Here, we report: 100% survival to >1 year and minimal residual pathological changes in the brain and spinal cord is achieved with few injections at high vector dose; that salutary outcomes correlate with prominent movement of corrective enzyme within perivascular and cerebrospinal fluid (CSF) spaces, within and along axonal tracts and diffusing from injection sites; classical signs of disease, namely spasticity and tremor/ataxia, can be corrected independently-finally, that in the absence of targeted delivery, emerging disease with pathological storage develops at peripheral sites in long-term survivors.
results Abundant activities of all three Hex isozymes are generated by intracranial coinfusion of 2/1 rAAVα + rAAVβ We infused 1-month-old mutant Sandhoff mice (SD) with rAAVβ or rAAVα + rAAVβ at a single site into the striatum and sacrificed them 4 weeks postinjection. Wild type and TSD animals were used as controls. Cerebrum or liver from controls, and transduced hemicerebrum were homogenized and tissue extracts subjected to ion-exchange chromatography or cellulose-acetate electrophoresis to separate Hex isozymes; the fluorogenic substrate 4-MUG was used to detect the activity of all three isozymes while 4-MUGS was used to indicate the presence of Hex A and S. We show that brain transduced with rAAVα+rAAVβ expresses abundant Hex A, Hex B, and Hex S isozymes. When rAAVβ alone was infused, expression of only the Hex B isozyme was detected (Figure 1a-d,f) . The expected pattern of mature α (α m ) and β (β m "a, " β m "b, " and β m "c") subunits was verified by polyacrylamide gel electrophoresis and western blotting with an antibody against Hex A on brain extracts and relevant fractions from chromatographic separation (Figure 1e) . We ascribe the interspecies isozyme mobility differences to variations in amino acid composition and the positively charged HIV1-tat domain fused to recombinant human β-hexosaminidase polypeptides. Dual in situ hybridization (ISH) fluorescence microscopy of rAAVα + rAAVβ-transduced brain sections with subunit-specific RNA probes showed that most transduced cells expressed both subunits, albeit at varying ratios (Figure 1g) . survival is enhanced in a rAAVα + rAAVβ dose and site-dependent manner We compared therapeutic outcomes of infusions of rAAVα + rAAVβ in 1-month-old SD mice according to distinct experimental protocols: unilaterally into the striatum (Sx1), bilaterally into the striatum (Sx2) or cerebellum (Cx2), and bilaterally into the striatum and cerebellum (S+C) or into the hippocampus and cerebellum (H+C). Mannitol was added as a coinfusate to aid rAAV diffusion. The same 2/1 rAAVα and rAAVβ vector batches were used throughout the study to reduce variability. Maintenance of body weight and coat condition was monitored regularly as indicators of well-being and fitness.
Survival was analyzed with the log-rank (Mantel-Cox) test: intracranial rAAV-mediated gene delivery has a marked effect on the life-span of this acute mouse model of GM2 gangliosidosis (P < 0.0001), as shown by the Kaplan-Meier plot (Figure 2a) . Survival of the different treatment groups was examined by one-way analysis of variance and adjusted for multiple post-hoc comparisons by the Bonferroni method. Median survival was 730 days for untreated normal controls (wild type and heterozygous) (n = 22) and 131 days for mutant animals [SD (UT)] (n = 37). In contrast, median survival of groups of SD mice treated according to the different protocols was in the order: S+C (681 days, n = 16); H+C (609 days, n = 8); Cx2 (595 days, n = 8); Sx2 (455 days, n = 8); Sx1 (194 days; n = 15). The vector delivery protocols with the best survival outcome were S+C and H+C with no significant difference between these cohorts (P > 0.05) suggesting that the accrued benefit was similar. The S+C combination was superior to either Sx2 or Cx2 alone (P < 0.05). Although no clear difference in apparent survival between H+C and Sx2 or Cx2 was returned (P > 0.05), the neurological effects of the interventions differed markedly between the groups. See Supplementary Table S1 for details on the cause of death in all animals in the study.
Long-term survival of mice injected bilaterally into a single structure, Sx2 and Cx2, was unexpected. Distribution of survival within the Cx2 group was particularly striking: the animals either overlapped with those singly injected or those with best outcomes in groups S+C and H+C as depicted in the scatter plot (Figure 2b) . Between groups Cx2 and Sx2 survival was not significantly different, but the manifestations of disease differed considerably. We attribute much of the variation in the outcome of single injections to technical difficulties inherent to the delivery of microlitre quantities manually into a small brain. However, even the best outcomes from single-site interventions were insufficient to secure long-term rescue of disease with its global effects in the nervous system.
Growth of mutant mice declines sharply during the last month of life, but successful rAAVα+rAAVβ treatment prevents this decline (Figure 2c and Supplementary Figure S1) .
Treated SD mice have reduced adipose tissue and are generally smaller than their normal littermates but grooming is well maintained and their coat appears healthy.
Biodistribution of vector and enzyme depends only partly on therapeutic modality
Transduced cells were identified by ISH with antisense and sense RNA probes against the common WPRE-BGHpA sequence. Tissue structures labeled by ISH are documented in Supplementary  Table S2 ; these are named using the nomenclature of Franklin and Paxinos. 28 Histochemical staining for β-hexosaminidase activity was carried out in consecutive sections. A systematic analysis was performed on sections from five S+C, one H+C, one Sx2, and two Cx2-injected animals.
Injections into the striatum induced widespread distribution of virus and enzyme. Staining was most intense at the injection site and interconnected areas. Dissemination was further amplified by the ability of the virus to disperse along white matter such as corpus callosum (Figure 3a) .
ISH and β-hexosaminidase activity labeled choroid plexus (Figure 3a (Figure 3f) . Furthermore, ISH and hexosaminidase staining was detected extracranially in periocular (Figure 3g ) and subcutaneous muscle of the eyelid (Figure 3h) , and the perineurium of cranial nerves such as the optic nerves (Figure 3g ). We attribute this to vector distribution via the CSF.
Viral infusions into the hippocampus led to ISH-labeling of the hippocampal formation and interconnected regions.
Injections into the deep cerebellar nuclei led to delivery of vector and enzyme to most layers of the cerebellar cortex and interconnected areas (Figure 4a,b) , but we also found diffusion or leakage of vector into adjacent cerebellar and brain stem white matter, such as middle cerebellar peduncle (Figure 4a) . Cells staining by ISH in white matter closely resembled oligodendrocytes, but may also represent other glia (Figure 4b ). Diffusion of virus extended into brain stem nuclei, with some variability encountered between animals and between injected hemispheres of the same animal (Figure 4a ).
Diffusion into structures adjacent to the deep cerebellar nuclei, particularly into the highly interconnected brain stem nuclei, might explain spread to unexpected brain regions. This proposition is best exemplified by results from Cx2-injected animals with contrasting functional outcomes. The brain of an animal with severe neurological disease (Supplementary Video S6), had ISH and Hex-specific staining which was highly restricted to the cerebellum; moreover abundant storage material was present in both sides of the brain, such as in the forebrain. In marked contradistinction, a mouse with few signs of disease (Supplementary Video S7), and strong ISH-labeling in the right cerebellum and brain stem had its entire right brain almost free of storage. In this animal, ISH staining was weak in the left cerebellum and almost absent in the left brain stem; more pathological storage was observed in the left side of the brain (Figure 4a and c, and Supplementary Figure S2) . Only a feint histochemical reaction for β-hexosaminidase activity was detectable under the microscope in either cerebral hemisphere of this mouse. Small differences in hexosaminidase activity, reflecting the asymmetric gene transduction of hindbrain, seem likely to account for the marked differences in the expression of disease in the brain observed within the same animal. In these studies, every attempt was made to infuse equal volumes of vector preparation bilaterally into the brain, but experience has long shown that the side first injected generally gives the strongest signal for vector genome by ISH and histochemical staining for β-hexosaminidase.
One of the most striking findings was that much of the distribution of β-hexosaminidase activity stain occurred in a pattern resembling that of cerebral blood vessels of various diameters, particularly notable in long-lived animals. tomato lectin, which selectively binds to endothelium. In brain regions where β-hexosaminidase appeared to be predominantly "perivascular, " e.g., in the forebrain (Figure 5a-c) and the brain stem (Figure 5a) , little storage or neuroinflammation could be found (Supplementary Figure S3) .
s+c or H+c viral infusions prevent the manifestations of GM2 gangliosidosis
We chose the S+C route because these structures have intricate connections with large regions of the brain early affected in GM2 gangliosidosis. The hippocampus, a critical centre for memory, is a discrete, self-contained unit and thus would limit virus and enzyme distribution. We reasoned that by comparing the therapeutic outcomes of these two interventions, the principal biodistribution pathways would be readily distinguished from alternative routes of dissemination. The brains and spinal cords of six long-surviving SD mice from groups S+C (five animals) and H+C (one animal) were examined histologically and stained with GM2 antibody or the periodic acid-Schiff (PAS) reagent to detect GM2 ganglioside and other stored glycoconjugates. Unexpectedly, there was a striking absence of neuronal storage in the brains and at all levels of the spinal cord in these aged mice (Supplementary Figure  S4 and Figure 5d) . Moreover, neuroinflammation, as assessed by the intensity and number of cells staining for the microglia/marcrophage (CD68) and astrocytic (GFAP) markers, was greatly reduced in treated animals compared with untreated SD mice (Supplementary Figure S3) . Irrespective of the intervention used to transfer the therapeutic genes, and where at all observed, the inflammatory response was local and commensurate with the levels of pathological storage (Figure 6a) . Absence of neuropathological changes directly correlated with preservation of neurological function in long-surviving Sandhoff mice (Supplementary Videos S1-S3).
tremor and ataxic gait can be segregated from spastic disease To determine the extent of disease rescue for a given brain region and whether it is possible to use gene transfer to discriminate between the different neurological manifestations of GM2 gangliosidosis anatomically, SD mice were injected with vector bilaterally at two distant, and poorly interconnected sites in the brain. These sites were the deep cerebellar nuclei (Cx2) or the striatum (Sx2). Positioned 6-mm apart, both regions are well connected to other parts of the brain and were expected to distribute the corrective enzyme widely-but with little overlap. The deep cerebellar nuclei carry the main output of the cerebellum and receive important inputs from Purkinje layer; the striatum has afferent connections and efferent output to key motor control areas such as motor cortex, thalamus, brainstem and other parts of basal ganglia. Throughout their lives, 30% of the Sx2-injected animals had no overt neurological signs and the remainder had mild tremor and ataxia which was delayed in onset, and remained stablemanifestations which indicate disease of the cerebellum or its connections (Supplementary Videos S4 and S5). Brain and spinal cord coronal sections from a representative SD animal aged 619 days with mild disease were stained with the PAS reagent at every 180 µm. These studies showed that most neurons in the brain and spinal cord were free of pathological storage, except for PASpositive cells in cerebellar cortex. Compared with the cerebellum of untreated animals at their humane end point the abundance of storage material was greatly diminished (Figure 6a) . In the spinal cord PAS-positive neurons were rare.
Two-thirds of Cx2-injected mice either had no overt disease or had a disease that consisted mainly of clasping of hind limbs when lifted by the tail; they walked with the body close to the ground. These signs remained unchanged throughout, and occurred in the absence of tremor or ataxia. Mean survival for this subgroup was 629 days. The remaining one third developed a severe and progressive wasting disease characterized by dragging of hind limbs with elevated pelvis, but without tremor or ataxia (Supplementary Video S6) . Animals in this adverse subgroup lost weight rapidly and required humane killing; mean survival was 229 days. The neurological signs in the Cx2-injected group indicate spasticity due to disease of cerebral cortical neurons or their connections. GM2 antibody staining of the brain and spinal cord from an animal with this wasting disease, showed the absence of storage material in the entire cerebellum and spinal cord. The brain stem, midbrain, thalamus and hypothalamus showed very little GM2 ganglioside but, commensurate with the neurological signs and behavior, storage-loaded cells were abundant in the cerebral cortex, hippocampus, and olfactory bulbs.
To investigate why some Cx2-injected animals appeared to escape disease and the putative association with specific patterns of glycoconjugate storage, brain and spinal tissue from one such mouse was also stained with the PAS reagent (Supplementary Video S7). While PAS-positive neurons in the right brain were scarce (few were present in the striatum, thalamus and cerebral cortex) more extensive involvement was observed in the same structures of the left brain (Figure 4c and Supplementary Figure  S2) . In the spinal cord PAS-positive neurons were rare.
long-term rescue of cns permits expression of other disease manifestations
Accumulation of undegraded glycoconjugates has been reported in kidney and liver of patients with SD and in experimental Sandhoff mice; we thus predicted that long-term surviving SD mice would show increased storage in these viscera. Large amounts of storage material were indeed present in these organs, but in addition we found pathology in cell types previously not considered to be affected. At its humane end point, the SD mouse retina shows positive PAS staining only in the ganglion cell layer, but in animals after gene therapy to rescue the central nervous system (CNS) disease, staining extended also to the inner nuclear layer (Figure 6b) . Similarly, in untreated SD mice, the endothelium of the brain and spinal cord appeared free of storage material or other abnormalities. Endothelium of SD mice more than 6 months of age and after gene therapy, stained strongly with the PAS reagent; this was associated with low β-hexosaminidase activity staining of these areas, even though local enzyme activity was clearly sufficient to maintain neighboring neurons and glial cells free of stored glycoconjugate. Endothelial cells appeared free of glycoconjugate where abundant β-hexosaminidase activity was present, such as at loci close to the site of injection (Figure 6c) . This would suggest that CNS endothelium is not refractory to enzyme uptake and storage correction, but rather a larger pool of β-hexosaminidase is necessary than for neighboring neurons and glia, possibly due to the blood-brain barrier. The endothelium of peripheral tissues in these animals also stained strongly with the PAS reagent.
Of the animals surviving >1 year with little or no overt neurological signs in groups S+C and H+C, more than one half developed an acute illness which was usually fatal within a few days. Postmortem examination revealed gross urinary and/or fecal retention with massive dilatation of the urinary bladder and/or colon (see Supplementary Table S1 for details). There was a slight predominance of male mice, compared with females, in relation to the urinary retention, but animals of both genders experienced fecal retention involving the small and large intestine, which we attribute to autonomic neuropathy. Detailed pathological examination by certified veterinarians failed to identify bacterial infections or any other cause of death. In this context however, it is notable that some animals remained healthy for at least 2 years.
dIscussIon
The GM2 gangliosidoses are emblematic lysosomal diseases which cause fatal neurodegeneration in young infants. Mice with SD show a latent phase during the first few months of life only to enter a phase of rapid decline which is lethal within 6 weeks. 15, 16, 29 This animal model thus constitutes an invaluable framework by which to explore and stringently test prospective therapies, such as gene transfer.
We and others have shown that intracranial application of gene-, 23, 27 cell-, 19, 20 and protein-22 based therapies can alleviate, albeit with marked differences in efficacy, the progressive accumulation of storage material and clinical signs in the GM2 gangliosidosis mouse models. Results from these studies have shown that resolution of pathology extends to regions beyond the primary source of enzyme. This is facilitated by secretion of β-hexosaminidase by competent cells into interstitial spaces that can then be recaptured by cells at a distance 30 -a property shared with other lysosomal hydrolases. We show here for the first time rescue of GM2 gangliosidosis in brain and spinal cord for up to 2 years in the acute Sandhoff mouse model by rAAV-mediated gene transfer. All three β-hexosaminidase isozymes were generated after coinjection of rAAVα and rAAVβ on a single occasion intracranially in young adult mice, and it is possible that some Hex A and Hex S could be chimeric due to coassembly with the endogenous mouse α subunit.
Our results show the value of exploiting the intricate interconnectivity of the brain to promote viral and enzyme distribution for diseases that affect the nervous system diffusely, as were those reported by others. 31, 32 However, by targeting gene therapy to specific structures, we were able to discriminate the tremor and ataxic signs from the spastic manifestations. Critically, very small differences in the amount and/or distribution of recombinant protein determine whether this intervention succeeds or fails. These findings suggest the existence of threshold effects in vivo-that restoration of a small percentage of wild-type activity would be sufficient to restore GM2 degradation to normal-and that small variations below this target would adversely affect the course of disease. 33 We observed a remarkable dissemination of therapeutic protein distributed through the perivascular space in the brain and spinal cord of Sandhoff mice. This route of enzyme movement appears to contribute importantly to maintaining neural tissue free of storage and inflammation. In support of our findings are studies by Lie and colleagues, who, after injecting rAAV4 into the lateral ventricle of MPS VII mice, showed recombinant β-glucuronidase in close association with brain microvasculature-which they attributed to CSF flow. 34 Broekman et al. also identified β-galactosidase in the perivascular space of VirchowRobin after hippocampal infusions of rAAV 2/1 in GM1 gangliosidosis mice. 35 Cserr and colleagues, and others, confirmed that radioactive tracers of different molecular weights injected into the brain parenchyma were distributed along perivascular spaces and cleared at similar rates-consistent with convective bulk flow, rather than diffusion. 36, 37 Recently, the purified lysosomal enzyme acid sphingomyelinase was injected into the lateral ventricles of the Rhesus macaque and was detected in perivascular spaces. 38 Here, we report that 2 years after rAAV infusions, choroid plexus, and brain parenchyma still expressed vector RNA and proteinand thus, β-hexosaminidase would be expected to be secreted into the CSF and interstitial parenchyma. Although we have not demonstrated "flow" of enzyme or the direction of the putative flow, the experimental evidence for its existence is very strong. Weller and colleagues have elegantly characterized perivascular flow in animal models of Alzheimer's disease, including mice transgenic for the human β-amyloid peptide. 39, 40 These findings, and those of others, [36] [37] [38] will guide the design of further experiments to define more precisely the perivascular route of enzyme transport and investigate its significance for the therapeutic outcomes in GM2 gangliosidosis that we find.
That the small viral dose injected was sufficient to transduce brain parenchyma extensively and that vector was also distributed widely via the CSF space, was unexpected. With few cells reacting positively for vector RNA by ISH and the absence of detectable glycoconjugates in neurons throughout the entire length of the spinal cord, secretion of β-hexosaminidase by choroid plexus is likely to have contributed substantially to the spread of enzyme. We cannot exclude the presence of some vector RNA in cells that was not detected by the ISH stain. Vector RNA and enzyme in dorsal root ganglia cell bodies correlate with prominent labeling of gray matter and roots in dorsal horn and corresponding spinal nerves. Similar distribution of horseradish peroxidase after infusion into the lateral ventricles or subarachnoid space of cats has been reported. 41, 42 The accepted view that substances in the CSF inevitably drain from subarachnoid space through arachnoid granulations and out into cerebral veins is not consistent with our findings. In agreement with other studies, our findings indicate that much of the CSF containing rAAV and/or protein travels along the meningeal sheaths such as those of cranial nerves, and drains into extracerebral tissue. 43 Having arrived at these sites, the virus is then able to enter permissive cells such as muscle. The brain is an immuno-privileged site but dissemination from the CNS to lymph tissue would allow direct access of potentially antigenic material with the possibility of inducing an immune response, 40 rendering immunosuppression an important consideration during the planning of clinical trials.
The strong lateralization of storage clearance in rostral brain structures after we injected rAAV into the hindbrain, suggests that in addition to the well-recognized motor fibers that decussate in the midbrain, ipsilateral fibers exist that can transport enzyme to these distant regions. We identified the transduced locus coeruleus as a potential source of this effect. This locus has ipsilateral projections with widespread distribution throughout the neuraxis 44 -and would be an excellent target for many gene therapy applications for diffuse CNS diseases.
We contend that the unprecedented survival and correction of the pathology achieved in the CNS in this acute animal model of GM2 gangliosidosis results from the exploitation of several routes of vector and protein distribution: axonal-, CSF-, and perivascular transport, as well as diffusion. Given that each neuron has its own capillary for oxygen and nutrient supply, we believe that the perivascular route merits further investigation.
We attribute the catastrophic visceral disease that occurred in some of the long-surviving mice to autonomic neuropathy. It is noteworthy that autonomic abnormalities have been reported in rare adults with human SD. 45 It has been estimated that to use AAV-mediated gene therapy for distributing lysosomal enzymes globally to the brain of an infant would require >50 individual intraparenchymal injections 31 and clearly for optimal clinical utility, improved means of delivery are required. To treat the human brain and spinal cord, we propose that a combination of convection-enhanced delivery to the parenchyma, 46 with intraventricular and/or intrathecal injections of rAAV vectors is more realistic. Here we have shown that coinfusion of monocistronic vectors, each expressing one or other of the human subunits is an effective means to secure appropriate HexA biosynthesis in vivo and offers a practical approach for treating the GM2 gangliosidoses. In relation to the Sandhoff, rather than the Tay-Sachs variant of GM2 gangliosidosis, the hitherto unknown emergence of peripheral disease in long-term survivors after the neurological features are corrected, should be taken into account-so that ultimately a combinatorial stratagem to treat systemic and CNS disease may be needed.
MAterIAls And MetHods
Experimental animals. The knockout SD mouse model (strain: B6; 129S-Hexbtm1Rlp) was obtained from the Jackson Laboratory (Bar Harbor, ME). 15 The strain was maintained by crossing homozygous males with heterozygous females or by heterozygous matings. These studies were conducted by using protocols approved under license by the U.K. Home Office (Animals Scientific Procedures Act, 1986). hexb genotyping was determined by PCR as previously described. 27 Mice were provided with nutritional supplements (Transgel; Charles River Laboratories, Margate, UK) on the cage surface.
The approved humane end point applied to mice throughout these studies, was defined as the loss of between 10 and 20% of presymptomatic body weight. Animals were killed at any time if they developed clinical signs such as visceral enlargement, tumors, and self-inflicted injuries or when they reached the age of 2 years.
Vector construction and production. Human cDNAs coding for the α and β subunits were fused at their 3′-ends to human immunodeficiency virus protein transduction domain, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), and bovine growth hormone polyadenylation signal (BGHpA), as described. 27 Recombinant AAV viruses were produced by triple plasmid cotransfection of HEK 293 cells as described. 27 Titers were 9 × 10 12 and 1.3 × 10 13 drps/ml for rAAV2/1α and rAAV2/1β, respectively.
Intracranial stereotaxic infusion of rAAV vectors. Four to five-week-old Sandhoff mice were anesthetized and placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA). Burr holes were drilled over target sites, and vector mix was delivered vertically by using coordinates relative to bregma and dura. Single-site injections into the striatum were at: anterior posterior (AP), −0.1 mm; medial-lateral (ML), −2.0 mm; and dorsal-ventral (DV) -3.0 mm. For bilateral injections, into the striatum, AP, −0.1 mm; ML, ±2.0 mm; and DV, −3.0 mm; the hippocampus, AP, −2.0; ML, ±1.5; DV, −2.5; and cerebellum, AP, −6.0 mm; ML, ±1.5 mm; DV, −3.0 mm. Animals received 3 µl of vector per site, volume ratio of 1.1: 1.1: 0.8 (rAAV2/1α: rAAV2/1β: 20% wt/vol mannitol), at 0.8 µl/minute infusion rate. The needle was withdrawn after 5 minutes. Animals were given postoperative analgesia (Rimadyl, Large Animal Solution; Pfizer, Kent, UK), and placed in an incubator at 37 °C to recover.
Tissue processing. Mice were killed and organs either snap-frozen on dryice or transcardially perfused with cold phosphate-buffered saline followed by 4% paraformaldehyde. Perfused tissue was post-fixed in the same fixative for a few hours and cryoprotected in 30% sucrose overnight at 4 °C. 15 or 45 µm coronal sections were cut and stored at −80 °C.
Ion-exchange chromatography and fluorimetric analysis. Unfixed tissue was weighed and homogenized at 8% (wt:vol) in cold and degased 10 mmol/l sodium phosphate (pH 6.0), containing 100 mmol/l NaCl and 0.1% Triton X-100. Extracts were loaded into a Resource Q column (# 17-1177-01; GE Healthcare, Little Chalfont, UK) and run in the fast performance liquid chromatography system ÄKTA Purifier 10 using the UNICORN 5.1 software package (GE Healthcare). After extensive washing with 2 mol/l NaCl followed by loading buffer, the column was developed with 10 ml of an NaCl gradient from 100 to 400 mmol/l, and 0.5 ml fractions collected and stored on ice until fluorimetrically analyzed. Five microliters of unfractionated lysate extracts and fractions were assayed for β-hexosaminidase activity with 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside (MU-GlcNAc, 4-MUG) (Biosynth AG, Kings Langley, UK) in 0.01 mol/l phosphate citrate buffer pH 4.4; and 4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-β-D-glucopyranoside (MU-GlcNAc-6-SO 4 , 4-MUGS) (Melford Laboratories, Ipswitch, UK) in 0.2 mol/l phosphate citrate buffer pH 4.0. Fluorescence was determined in a Perkin Elmer Precisely 1420 Multilabel Counter Victor 3 (excitation: 355 nm; emission: 460 nm).
Polyacrylamide gel electrophoresis and cellulose-acetate electrophoresis. For polyacrylamide gel electrophoresis, tissue extracts were run in 4-15% linear gradient gels (#161-1122; Bio-Rad, Hemel Hempstead, UK) in the presence of sodium dodecyl sulfate. Western blots were processed with goat polyclonal antihuman HexA antibody (kindly donated by Dr R.L. Proia) which detects both α and β subunits 26 and secondary antibody rabbit anti-goat-HRP (1/5,000; DakoCytomation, Ely, UK). Blots were developed with LumiGLO chemiluminescent substrate (KPL).
Tissue extracts, containing between 100 and 250 µg of protein were applied to a cellulose-acetate gel (Cellogel; Accurate Chemical & Scientific, Westbury, UK), run in 20 mmol/l phosphate buffer pH 7.0, and incubated in 20 mmol/l citrate-phosphate buffer pH 4.4, containing 2.5 mmol/l 4-MUG substrate at 37 °C for 1 hour. Enzyme activity was visualized as fluorescence under UV light, essentially as described. 26 Protein was quantified by the Pierce protein assay (MicroBCA Reagent).
Histological staining. For nonperfused tissue, sections were warmed up at room temperature for ~30 minutes and fixed in cold 4% paraformaldehyde for 10 minutes before staining. β-Hexosaminidase activity was detected with naphthol AS-BI N-acetyl-β-glucosaminide (Sigma, Poole Dorset, UK); 47 and for dual detection of blood vessels, sections were then incubated with fluorescein-conjugated tomato lectin (1/100; Lycopersicon esculentum; Vector Laboratories, Peterborough, UK). PAS (Sigma) stained sections were counterstained with hematoxylin. Before mounting in dibutyl phthalate xylene from BDH, sections were dehydrated and cleared with a series of ethanols and xylene. Lectin-labeled sections were directly mounted in diamidino-2-phenylindole containing ProLong Gold antifade reagent (Invitrogen, Paisley, UK) and images collected with a NIKON TE-300 fluorescence microscope (Nikon, Kingston, UK).
Immunohistological staining was performed with mouse monoclonal anti-N-acetyl-GM2 immunoglobulin M (MK1-16; Seikagaku, Tokyo, Japan; 1/100), rat anti-mouse CD68 (MCA1957; Serotec, Oxford, UK; 1/50), goat anti-GFAP (N-18, Santa Cruz Biotechnology, Calne, UK; 1/50) as primary antibodies. Staining was based on the avidin-biotin peroxidase technique (Vectastain ABC HP kit; Vector Laboratories), developed with 3′-diaminobenzidine and counterstained with Cresyl violet. Biotinylated secondary antibodies were goat anti-mouse immunoglobulin M µ-chain (Jackson ImmunoResearch, Newmarket, UK), rabbit anti-rat IgG and rabbit anti goat IgG from Vector Laboratories. Slides were mounted with dibutyl phthalate xylene as described above.
ISH was performed with digoxigenin or fluorescein labeled riboprobes against the WPRE-BGHpA sequence, present in both rAAVα and rAAVβ vectors, or against human β-hexosaminidase α (684 bases long; cDNA positioned 782-1,466) or β (852 bases long; cDNA positioned 314-1,166) subunit sequences. 48 ISH-positive cells were detected by colorimetric staining with alkaline phosphatase-mediated BCIP (5-bromo-4-chloro-3-indolylphosphate)-nitroblue tetrazolium reaction, essentially as described 49 or tyramide signal amplification reagent (TSA) following manufacturer's recommendations. Fluorescein-TSA and cyanine 3-TSA were from Perkin Elmer, Waltham, MA (TSA kits) and anti-digoxigenin-POD and antifluorescein-POD were from Roche (Burgess Hill, UK). Sections were directly mounted in diamidino-2-phenylindole containing ProLong Gold antifade reagent and images collected with NIKON TE-300 fluorescence microscope and confocal Leica TCS SPE (Leica Microsystems, Milton Keynes, UK).
Statistics. The Kaplan-Meier survival curve was analyzed with the log-rank equivalent to the Mantel-Cox test. The statistics were analyzed with oneway analysis of variance and Bonferroni multiple post-hoc comparisons. Statistical analyses were performed with GraphPad Prism v5.0 (GraphPad Software). Values with P < 0.05 were considered significant.
The mean value of weekly weights, across all mice in each group, is calculated for each week of age along with the associated SE, and the mean ± 1.96 SE are plotted against the mid-point of each week. Assuming individual observations within each week to be independent and normally distributed, the vertical bars represent 95% confidence intervals for the estimated means.
suPPleMentArY MAterIAl Figure S1 . Comparison of average weekly weights between controls and rAAVα+rAAVβ-injected mice. Figure S2 . Pattern of vector RNA expression and glycoconjugate storage in a Cx2-injected Sandhoff mouse. Figure S3 . Glycoconjugate storage and neuroinflammation is decreased at sites with prominent perivascular β-hexosaminidase. .  Table S1 . Cause of death of the animals in this study. Table S2 . Structures stained for vector RNA by in situ hybridization (ISH) after Cx2, Sx2, and H+C injections into Sandhoff mice. Video 1. Untreated SD mouse at the humane end point of 120 days of age. Video 2. S+C-treated SD mouse at 1 year of age. Classical features of disease are absent. Video 3. The same S+C-treated mouse as in Supplementary Video S2 seen here at 2 years of age accompanied by untreated normal littermate. Video 4. Sx2-treated SD mouse at 1 year of age. Video 5. The same Sx2-treated mouse as in video 4 at 20 months of age. Video 6. Cx2-treated SD mouse at the humane end point of 265 days of age. Video 7. Cx2-treated SD mouse at 1 year of age.
